Roche Holding (SWX:ROP) has entered into a collaboration with C4 Therapeutics to develop degrader antibody conjugates for ...
An experimental drug designed to silence a gene strongly linked to Parkinson's disease has shown encouraging effects in a ...
Nurix Therapeutics, Inc. has reported past first-quarter 2026 results showing revenue of US$6.25 million versus US$18.45 million a year earlier, alongside a wider net loss of US$87.17 million and a ...
Morning Overview on MSN
Researchers find some cancer drugs work differently than their stated targets
As of spring 2026, a cancer drug that has spent years in clinical development as a Wnt/beta-catenin pathway blocker has been ...
Pharmaceutical Technology on MSN
Roche and C4 Therapeutics to advance degrader-antibody conjugates research
C4 Therapeutics will receive $20m upfront in addition to milestone payments, with a potential $1bn in additional milestones.
C4 Therapeutics (CCCC) stock is in focus as the company is in pact with Roche (RHHBY) for degrader-antibody conjugates, a new ...
Agreement Focused on Developing DACs With Payloads For Two Oncology Targets, With an Option for a Third TargetC4T to Develop Degraders With ...
Roche has joined its Big Pharma peers in the emerging degrader-antibody conjugate (DAC) space, paying C4 Therapeutics $20 ...
Posters plastering the room, a persistent, vivacious chatter — at the March New England Science Symposium, what might have seemed like a tornado of unrelated ideas and academic entropy were actually ...
“Setidegrasib is the first drug in this KRAS degrader class targeting KRAS G12D in solid tumors,” lead investigator Wungki ...
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive memory loss, cognitive decline, and behavioral changes. The deficits linked to AD are known to result from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results